38 results about "Fibromyalgia" patented technology

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin or a metabolite thereof, and related uses of the psychedelics. The disclosure in some aspects also relates to methods for identifying subjects for treatment of fibromyalgia with administration of psychedelics. In some aspects, the treatment also involves psychotherapy. In some aspects, the subject receiving the treatment is assessed for various indicators, such as observer-rated and subject-reported outcomes, biological and clinical indicators, and combinations thereof.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Disclosed herein include methods, compositions, and kits suitable for use in treating fibromyalgia. In some embodiments, the method comprises the administration of a composition comprising ketamine, norketamine and a pharmaceutically acceptable salt thereof. In some embodiments, the composition is an extended-release formulation, such as an implant.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. Tire methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and / or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same for treating drug addiction, drug dependence, drug overdose, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity.

The current disclosure address a need in the art by providing methods and compositions for treating migraines and certain pain-related disorders with a combination therapy. Accordingly, aspects of the disclosure relate to a method for treating a migraine, post-traumatic headache, or chronic pain syndrome patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator and a calcitonin gene-related peptide (CGRP) inhibitor. Further aspects relate to a composition comprising insulin-like growth factor-1 (IGF-1) and a CGRP inhibitor. Also provided are methods for treating fibromyalgia or chronic fatigue syndrome in a patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator.

The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive / indicative of FM in the individual.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same to treat drug addiction, drug dependence, drug excess, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity. (I)

The present disclosure relates to diagnostic and therapeutic applications of photobiomodulation and light therapies such as red-light therapy and electrical stimulation devices. Application areas include gut, uterine and other pelvic conditions, back pain, endometriosis, fibromyalgia, etc. The methods and devices disclosed herein are used for delivering targeted therapy using personalized and adjustable treatment protocols which may use features such as real-time monitoring and closed-loop feedback. The devices described herein can be worn discretely to deliver therapy. The present disclosure also includes artificial intelligence and machine learning-based methods for such diagnostic and therapeutic applications.

The present disclosure provides methods of preventing or treating a patient having Long COVID comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti -interleukin-6 (anti-IL-6) antibody. The method described herein can prevent or treat Long COVID associated symptoms or diseases such as postural orthostatic tachycardia syndrome (POTS), brain fog, post-exertional malaise, aerobic metabolism impairment or deficiency, Chronic Fatigue Syndrome (CFS), fibromyalgia, and Mast cell activation syndrome (MCAS).

Described herein are methods of treating fibromyalgia, comprising administering esreboxetine to a human being in need thereof. Esreboxetine may also be used in the manufacture of a medicament for the treatment of fibromyalgia.

To provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia.SOLUTION: A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome and fibromyalgia, comprising 2-amino-2 - [2 - (4-heptyloxy-3-trifluoromethylphenyl) ethyl] propane-1, 3-diol or pharmaceutically acceptable salts thereof.SELECTED DRAWING: Figure 1

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

The present invention comprises excluding fibromyalgia patients in clinical studies for patients with lupus, treating the patients for lupus, and increasing the effectiveness of the lupus treatment by excluding patients with fibromyalgia. This makes the SELENA-SLEDAI and BILAG unreliable instruments for assessing the effectiveness of lupus interventions.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the autonomic nervous system. The focused ultrasound signal can have a mechanical index of between about 0.1 to about 5.0 and / or an acoustic pressure of between about 0.1 MPa to about 2.5 MPa. The medical condition can comprise chronic or refractory rhinitis, chronic rhinosinusitis, autonomic instability / autonomic dysfunction, functional gastrointestinal disorders, inflammatory disorders, immune disorders (including improving cancer and infections by neuromodulation of immune function), complex regional pain syndrome, post-traumatic stress disorder (PTSD), anxiety and anxiety-associated disorders, autism, fibromyalgia, uterine function, metabolic disorder, urinary incontinence or binge eating.

The digital therapy system collects data about the user from a user device. For example, the digital therapy system may collect data about the user's physical and mental health from the user through the user device. The digital therapy system then generates biomarker characteristics for the user. Biomarker characteristics are characteristics that describe a user's FM. The digital therapy system may generate the biomarker characteristics for a user by applying a biomarker model to data about the user. The digital therapy system can use the biomarker characteristics to determine a treatment plan for the user. A treatment plan is a set of treatment assignments that aid a user in alleviating or coping with symptoms from their FM in accordance with CBT techniques. The digital therapy system may also adjust the treatment plan for the user based on additional data that the digital therapy system receives.

The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2 (1H)-yllethanone, and / or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.

The invention discloses a fibromyalgia biomarker and therapeutic target mining system, which is characterized in that a plurality of pieces of GWAS data are acquired, data integration is performed by using a fixed effect reverse variance weighting method, summarized level whole genome association analysis data of four phenotypes are acquired, and a plurality of pieces of GWAS data are acquired; the genetic relevance among the four phenotypes is calculated through a genetic relevance analysis module based on a multivariable linkage imbalance score regression algorithm, genetic similarity and difference among different phenotypes are deeply analyzed, the relevance of the phenotypes on the genetic level is obtained, the shared genetic basis among the four phenotypes is revealed, and the genetic relevance among the four phenotypes is obtained. The method comprises the following steps: constructing a genome structure equation model through a shared genetic factor modeling module on the basis of genetic correlation, identifying shared genetic factors of four phenotypes of fibromyalgia, insomnia, anxiety and depression, and identifying biomarkers and potential treatment targets related to the shared genetic factors according to Mendel randomization analysis.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.

Described herein are formulations for treating, preventing, or ameliorating one or more of irritable bowel syndrome (IBS), rheumatoid arthritis (RA), fibromyalgia, post-traumatic stress disorder, PTSD

The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of subjects over 50 suffering from chronic fatigue, particularly due to: arthritis / chronic arthritis; heart disease; post-operative convalescence; depression; diabetes; fibromyalgia; chronic rheumatic diseases; stroke; cerebral ischemia; respiratory failure; chronic respiratory disease; allergic diseases; overweight / obesity; drug use, wherein said subjects are not suffering from Long-Covid / fatigue post Covid-19 syndrome.

Biomarkers for post-traumatic stress disorder (PTSD) and biomarkers for fibromyalgia (FM), which is associated with a high rate of PTSD, have been identified by narrowing down biomarker genes from PTSD-related gene database on the basis of biological events related to disease conditions. In addition, Chinese herbal medicines that are potential therapeutic agents for PTSD have been identified through the examination and comparison of gene induction by Chinese herbal medicines and antipsychotics in human keratinocytes. The present method can provide: biomarkers applicable as indicators for the diagnosis and the development of therapeutic agents for PTSD and FM; effective Chinese herbal medicines for PTSD and FM; and a screening method for therapeutic agents for PTSD and FM.

The present invention aims to provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia. A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome, and fibromyalgia, containing 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

Compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NM / DARs) are disclosed. In some cases, the compounds selectively target GluN2B over GluN2A, GluN2C, and / or GluN2D. Generally, the compounds possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a condition, disorder or disease using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, acute CNS injury, spinal cord injury, traumatic brain injury, coronary artery bypass graft, persistent or chronic cough, substance abuse disorder, opiate withdrawal, opiate tolerance, bipolar disorder, suicidal ideation, pain, fibromyalgia, depression, postpartum depression, resting tremor, dementia, epilepsy, seizure disorder, movement disorder, and neurodegenerative disease.